Not yet recruiting
Optimizing the Use of Aspirin for the Prevention of Preeclampsia
NCT07665853· Phase 3· Hospital Universitari Vall d'Hebron Research Institute· Source
Contact: Eva Lopez-Quesada
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
NCT07479329· Institut d'Investigacions Biomèdiques August Pi i Sunyer· Source
Contact: Verónica Perea, MD, PhD
Not yet recruiting
Treatment for Ph-negative ALL for Adults up to 65 Years
NCT07443592· PETHEMA Foundation· Source
Contact: Ferran Vall-llovera, Dr (principal investigator)
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Recruiting
RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE/INFLAMMATORY OSTEOARTHRITIS OF THE HANDS. MOTHER Study.
2025-521802-17-00· Phase 3· Farmalider S.A.· Source
Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source
Not yet recruiting
CGM Accuracy in Pregnancy Study
NCT07269015· Hospital Mutua de Terrassa· Source
Contact: Verónica Perea, MD, PhD
Not yet recruiting
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
NCT07082452· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Recruiting
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524· Phase 2· Regeneron Pharmaceuticals· Source
Not yet recruiting
Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler
NCT05284474· Hospital Universitari Vall d'Hebron Research Institute· Source
Contact: Eva Lopez
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931· Phase 2· Gilead Sciences· Source
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020· Phase 3· Pfizer· Source
Recruiting
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
NCT05558319· Phase 3· PETHEMA Foundation· Source
Contact: Josep Mª Martí Tutusaus, Dr
Active, not recruiting
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT
2024-517008-12-00· Phase 3· Fundacion PETHEMA· Source
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
NCT01952223· Phase 3· UNICANCER· Source
Recruiting
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
NCT02832245· Manuel Monreal· Source
Contact: S&H Medical Science Service